Nov 19, 2010 · The Thalidomide-Dexamethasone (TD) regimen has provided encouraging results in relapsed MM. To improve results, bortezomib (Velcade) has ...
Apr 12, 2012 · The superior efficacy of VTD versus TD as induction was retained despite readministration as consolidation therapy after double autologous transplantation.
Missing: (Velcade relapsing
People also ask
What is the difference between Velcade and bortezomib?
Bortezomib is a type of targeted cancer drug. It is also known as Velcade. It is a treatment for myeloma and mantle cell lymphoma. You pronounce bortezomib as bor-teh-zoh-mib.
Why is dexamethasone given with bortezomib?
Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
How effective is bortezomib for multiple myeloma?
Real-world progression-free survival (median 37.2 months with once-weekly versus 39.6 months with twice-weekly, p = 0.906) and overall survival (medians not reached in either cohort, p = 0.800) were comparable. PN rates were higher in patients receiving twice-weekly bortezomib (34.7% versus 18.5%, p < 0.001).
How does Velcade help multiple myeloma?
Velcade works by inhibiting enzyme complexes called proteasomes. Both normal cells and cancer cells contain proteasomes, which break down damaged and unwanted proteins into smaller components.
The Thalidomide-Dexamethasone (TD) regimen has provided encouraging results in relapsed MM. To improve results, bortezomib (Velcade) has been added to the ...
Conclusion: VTD was more effective than TD in the treatment of patients with MM with progressive or relapsing disease post-ASCT but was associated with a higher ...
Missing: superior | Show results with:superior
Dec 10, 2010 · VTD induction therapy before double autologous stem-cell transplantation significantly improves rate of complete or near complete response.
Bortezomib (Velcade (R))-Thalidomide-Dexamethasone (VTD) versus Thalidomide-Dexamethasone to treat multiple myeloma (MM) patients progressing or relapsing ...
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation ...
Lenalidomide-bortezomib-dexamethasone resulted in partial response or better in nearly two-thirds of relapsed/refractory myeloma patients.
Aug 21, 2024 · All transplant-eligible multiple myeloma patients should receive a triplet induction therapy (immunomodulatory agents, proteasome inhibitors, ...
The Eastern Cooperative Oncology Group E1A05 clinical trial addresses the potential role of bortezomib and dexamethasone (VD) or VD plus lenalidomide (VRD) as ...